Franchise opportunities compared

    Galt Pharmaceuticals vs Multivista

    Reviewed figures from each brand's Franchise Disclosure Document (FDD), side by side. Each figure carries its FDD year and page. This is not a ranking or recommendation, and the two FDDs may cover different years and location groups.

    Initial investment · Item 7

    Galt Pharmaceuticals

    $122,350 – $348,700

    2026 FDD · Item 7 · PDF p. 21

    Multivista

    $233,017 – $701,150

    2026 FDD · Item 7 · PDF p. 31

    Initial franchise fee · Item 5

    Galt Pharmaceuticals

    $100,000

    2026 FDD · Item 5 · PDF p. 13

    Multivista

    $20,000

    2026 FDD · Item 5 · PDF p. 16

    Royalty · Item 6

    Galt Pharmaceuticals

    Not available

    Multivista

    18% or flat-rate min

    2026 FDD · Item 6 · PDF p. 18

    Before you compare

    • Both sets of figures come from 2026 FDDs.
    • Only Galt Pharmaceuticals has reviewed Item 19 figures here.

    Financial commitment

    Estimated initial investment (Item 7)

    Galt Pharmaceuticals

    $122,350 – $348,700
    Total initial investment: $122,350 to $348,700
    2026 FDD · Item 7 · PDF p. 21

    Multivista

    $233,017 – $701,150
    TOTAL ESTIMATED INITIAL INVESTMENT
    2026 FDD · Item 7 · PDF p. 31
    Standard initial franchise fee (Item 5)

    Galt Pharmaceuticals

    $100,000
    The FDD also lists a past-fiscal-year initial franchise fee range of $125,000 to $300,000.
    2026 FDD · Item 5 · PDF p. 13

    Multivista

    $20,000
    The fee increases by population above 500,000 persons, with additional amounts per 100,000 persons or portion thereof.
    2026 FDD · Item 5 · PDF p. 16
    Royalty (Item 6)

    Galt Pharmaceuticals

    Not available
    No reviewed royalty record

    Multivista

    18% or flat-rate min
    Royalty percentage of in-territory gross sales
    2026 FDD · Item 6 · PDF p. 18
    Brand / advertising fund (Item 6)

    Galt Pharmaceuticals

    $1,000
    Marketing Fee maximum: $1,000 per month per territory
    2026 FDD · Item 6 · PDF p. 15

    Multivista

    2%
    Advertising Contribution — 2%
    2026 FDD · Item 6 · PDF p. 20

    System scale & health

    Total outlets (Item 20)

    Galt Pharmaceuticals

    63
    Outlets at end of 2025
    2026 FDD · Item 20 · PDF p. 48

    Multivista

    69
    Outlets at end of 2025
    2026 FDD · Item 20 · PDF p. 68
    Net outlet change (Item 20)

    Galt Pharmaceuticals

    −3
    Calculated: 66 at end of 2023 → 63 at end of 2025

    Multivista

    +65
    Calculated: 4 at end of 2023 → 69 at end of 2025
    Outlet exits (Item 20)

    Galt Pharmaceuticals

    0
    Closures, terminations & non-renewals in 2025 · Calculated turnover 0.0% of outlets at start of year
    2026 FDD · Item 20 · PDF p. 48

    Multivista

    Not available
    No complete exit records for a year
    Franchising since (Item 1)

    Galt Pharmaceuticals

    Not available
    Not in reviewed records

    Multivista

    Not available
    Not in reviewed records
    Franchisor founded (Item 1)

    Galt Pharmaceuticals

    Not available
    Not in reviewed records

    Multivista

    Not available
    Not in reviewed records

    Financial performance (Item 19), by location group

    Galt Pharmaceuticals
    Locations counted not stated in the reviewed record — Bottom third of 24 Operational Franchise Outlets; reporting period 2025.
    $12,142
    other Bottom third
    2026 FDD · Item 19 · PDF p. 46
    Locations counted not stated in the reviewed record — Middle third of 24 Operational Franchise Outlets; reporting period 2025.
    $66,763
    other Middle third
    2026 FDD · Item 19 · PDF p. 46
    Locations counted not stated in the reviewed record — Top third of 24 Operational Franchise Outlets; reporting period 2025.
    $813,752
    other Top third
    2026 FDD · Item 19 · PDF p. 46
    +1 more groups in the full report
    Multivista

    Not disclosed — no Item 19 financial performance representation

    Item 19 groups are shown separately and never combined. Revenue or sales figures are not profit. Net outlet change and turnover are Franopolis calculations from the disclosed counts; turnover is a count-based rate, not a measure of owner earnings.

    Galt Pharmaceuticals vs Multivista: common questions

    Which costs less to open, Galt Pharmaceuticals or Multivista?
    Galt Pharmaceuticals: $122,350 – $348,700 (2026 FDD · Item 7 · PDF p. 21); Multivista: $233,017 – $701,150 (2026 FDD · Item 7 · PDF p. 31). These are each franchisor's Item 7 estimated initial investment. The low end of the disclosed estimate is lower for Galt Pharmaceuticals. Estimates are not quotes, and the FDD years may differ.
    Which has more locations, Galt Pharmaceuticals or Multivista?
    Galt Pharmaceuticals: 63 (2026 FDD · Item 20 · PDF p. 48); Multivista: 69 (2026 FDD · Item 20 · PDF p. 68). Total outlets from Item 20. Outlet counts do not indicate territory availability or franchisee results.
    Do Galt Pharmaceuticals and Multivista disclose financial performance (Item 19)?
    Galt Pharmaceuticals has reviewed Item 19 figures for 4 location groups; Multivista makes no Item 19 financial performance representation. Different location groups are not directly comparable, and revenue is not profit.

    Answers restate the reviewed figures above. Not a ranking or recommendation.

    How Franopolis reviews FDD figures

    Keep researching